BACKGROUND: Expanded access to combination antiretroviral therapy (ART) in resource-poor settings is dependent on task shifting from doctors to other health-care providers. We compared outcomes of nurse versus doctor management of ART care for HIV-infected patients. METHODS: This randomised non-inferiority trial was undertaken at two South African primary-care clinics. HIV-positive individuals with a CD4 cell count of less than 350 cells per microL or WHO stage 3 or 4 disease were randomly assigned to nurse-monitored or doctor-monitored ART care. Patients were randomly assigned by stratified permuted block randomisation, and neither the patients nor those analysing the data were masked to assignment. The primary objective was a composite endpoint of treatment-limiting events, incorporating mortality, viral failure, treatment-limiting toxic effects, and adherence to visit schedule. Analysis was by intention to treat. Non-inferiority of the nurse versus doctor group for cumulative treatment failure was prespecified as an upper 95% CI for the hazard ratio that was less than 1.40. This study is registered with ClinicalTrials.gov, number NCT00255840. FINDINGS:408 patients were assigned to doctor-monitored ART care and 404 to nurse-monitored ART care; all participants were analysed. 371 (46%) patients reached an endpoint of treatment failure: 192 (48%) in the nurse group and 179 (44%) in the doctor group. The hazard ratio for composite failure was 1.09 (95% CI 0.89-1.33), which was within the limits for non-inferiority. After a median follow-up of 120 weeks (IQR 60-144), deaths (ten vs 11), virological failures (44 vs 39), toxicity failures (68 vs 66), and programme losses (70 vs 63) were similar in nurse and doctor groups, respectively. INTERPRETATION: Nurse-monitored ART is non-inferior to doctor-monitored therapy. Findings from this study lend support to task shifting to appropriately trained nurses for monitoring of ART. FUNDING: National Institutes of Health; United States Agency for International Development; National Institute of Allergy and Infectious Diseases. Copyright 2010 Elsevier Ltd. All rights reserved.
RCT Entities:
BACKGROUND: Expanded access to combination antiretroviral therapy (ART) in resource-poor settings is dependent on task shifting from doctors to other health-care providers. We compared outcomes of nurse versus doctor management of ART care for HIV-infectedpatients. METHODS: This randomised non-inferiority trial was undertaken at two South African primary-care clinics. HIV-positive individuals with a CD4 cell count of less than 350 cells per microL or WHO stage 3 or 4 disease were randomly assigned to nurse-monitored or doctor-monitored ART care. Patients were randomly assigned by stratified permuted block randomisation, and neither the patients nor those analysing the data were masked to assignment. The primary objective was a composite endpoint of treatment-limiting events, incorporating mortality, viral failure, treatment-limiting toxic effects, and adherence to visit schedule. Analysis was by intention to treat. Non-inferiority of the nurse versus doctor group for cumulative treatment failure was prespecified as an upper 95% CI for the hazard ratio that was less than 1.40. This study is registered with ClinicalTrials.gov, number NCT00255840. FINDINGS: 408 patients were assigned to doctor-monitored ART care and 404 to nurse-monitored ART care; all participants were analysed. 371 (46%) patients reached an endpoint of treatment failure: 192 (48%) in the nurse group and 179 (44%) in the doctor group. The hazard ratio for composite failure was 1.09 (95% CI 0.89-1.33), which was within the limits for non-inferiority. After a median follow-up of 120 weeks (IQR 60-144), deaths (ten vs 11), virological failures (44 vs 39), toxicity failures (68 vs 66), and programme losses (70 vs 63) were similar in nurse and doctor groups, respectively. INTERPRETATION: Nurse-monitored ART is non-inferior to doctor-monitored therapy. Findings from this study lend support to task shifting to appropriately trained nurses for monitoring of ART. FUNDING: National Institutes of Health; United States Agency for International Development; National Institute of Allergy and Infectious Diseases. Copyright 2010 Elsevier Ltd. All rights reserved.
Authors: Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Bruce E Landon; Ira B Wilson; Keith McInnes; Mary Beth Landrum; Lisa R Hirschhorn; Peter V Marsden; Paul D Cleary Journal: Arch Intern Med Date: 2005-05-23
Authors: Andrew Boulle; Catherine Orrel; Richard Kaplan; Gilles Van Cutsem; Matthew McNally; Katherine Hilderbrand; London Myer; Matthias Egger; David Coetzee; Gary Maartens; Robin Wood Journal: Antivir Ther Date: 2007
Authors: Adamson S Muula; John Chipeta; Seter Siziya; Emmanuel Rudatsikira; Ronald H Mataya; Edward Kataika Journal: BMC Health Serv Res Date: 2007-12-19 Impact factor: 2.655
Authors: Johan van Griensven; Ludwig De Naeyer; Jeanine Uwera; Anita Asiimwe; Claire Gazille; Tony Reid Journal: BMC Pediatr Date: 2008-10-02 Impact factor: 2.125
Authors: Gadzikanani Monyatsi; Paul C Mullan; Benjamin R Phelps; Michael A Tolle; Edwin M Machine; Floriza F Gennari; Jenny Makosky; Gabriel M Anabwani Journal: S Afr Med J Date: 2011-12-14
Authors: Gelane Workneh; Leah Scherzer; Brianna Kirk; Heather R Draper; Gabriel Anabwani; R Sebastian Wanless; Haruna Jibril; Neo Gaetsewe; Boitumelo Thuto; Michael A Tolle Journal: AIDS Care Date: 2012-04-26
Authors: S D Lawn; A D Harries; B G Williams; R E Chaisson; E Losina; K M De Cock; R Wood Journal: Int J Tuberc Lung Dis Date: 2011-05 Impact factor: 2.373
Authors: Ann E Kurth; John E Sidle; Nok Chhun; John A Lizcano; Stephen M Macharia; Meghan M Garcia; Ann Mwangi; Alfred Keter; Abraham M Siika Journal: AIDS Educ Prev Date: 2019-10
Authors: Vivek Jain; Dathan M Byonanebye; Gideon Amanyire; Dalsone Kwarisiima; Doug Black; Jane Kabami; Gabriel Chamie; Tamara D Clark; James F Rooney; Edwin D Charlebois; Moses R Kamya; Diane V Havlir Journal: AIDS Date: 2014-09-24 Impact factor: 4.177
Authors: Larry W Chang; David Serwadda; Thomas C Quinn; Maria J Wawer; Ronald H Gray; Steven J Reynolds Journal: Lancet Infect Dis Date: 2013-01 Impact factor: 25.071